Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00447057
First received: March 9, 2007
Last updated: September 12, 2011
Last verified: September 2011

March 9, 2007
September 12, 2011
March 2007
July 2010   (final data collection date for primary outcome measure)
Progression Free Survival (PFS) [ Time Frame: Baseline to date of measured PD or death from any cause. Maximum follow-up was from baseline to 32.2 months ] [ Designated as safety issue: No ]
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria using computed tomography (CT) or magnetic resonance imaging (MRI) for objective determination of progressive disease (PD: ≤20% increase in sum of longest diameter of target lesion). For participants alive as of data cut-off date who did not have PD, PFS was censored at date of last CT/MRI. For participants who received subsequent systemic anticancer therapy (after study discontinuation) prior to PD or death, PFS censored at date of last CT/MRI prior to initiation of post discontinuation systemic anticancer therapy.
To evaluate progression free survival between the 2 treatment arms
Complete list of historical versions of study NCT00447057 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate) [ Time Frame: Baseline to measured PD. Maximum follow-up was from Baseline to 34 months ] [ Designated as safety issue: No ]

    Per RECIST:

    CR: Disappearance of all target lesions; PR: Either a) ≤30% decrease in sum of longest diameter (LD) of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) of ≥1 nontarget lesions. In either case, no new lesions may have appeared.

    SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.

    PD: ≤20% increase in sum of LD of target lesions. Disease Control Rate (%) = (SD+PR+CR)/number of participants in arm*100.

  • Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate) [ Time Frame: Baseline to measured progressive disease. Maximum follow-up was from Baseline to 34 months ] [ Designated as safety issue: No ]

    CR: Disappearance of all tumor lesions; PR: Either a) at least a 30% decrease in sum of LD of target lesions or b) complete disappearance of target lesions, with persistence (but not worsening) ≥1 nontarget lesions. In either case, no new lesions may have appeared.

    SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.

    PD: ≤20% increase in the sum of LD of target lesions. Response Rate (%) = (CR+PR)/number of participants in arm*100.

  • Time to Treatment Failure (TTTF) [ Time Frame: Baseline to first date among death from any cause, PD, or study treatment discontinuation for any reason other than "protocol complete" or "satisfactory response". Maximum follow-up was from Baseline to 32.2 months ] [ Designated as safety issue: No ]
    Defined as the time from randomization to death from any cause, first observation of PD, or study treatment discontinuation due to any reason other than "protocol complete" or "satisfactory response". For participants who discontinued due to "protocol complete" or "satisfactory response", or for participants not known to have discontinued as of the data cut-off date, TTTF was censored at the last contact date.
  • Overall Survival (OS) [ Time Frame: Baseline to date of death from any cause. Maximum follow-up was from Baseline to 42.6 months. ] [ Designated as safety issue: No ]
    OS time is the duration from randomization to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date, OS was censored at the date of last contact.
  • Percentage of Participants Surviving at 1 Year [ Time Frame: Baseline to date of death from any cause up to 1 year ] [ Designated as safety issue: No ]
    Overall Survival (OS) rate at 1 year from the date of randomization was determined using the distribution of OS times and was estimated using the Kaplan-Meier method.
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Baseline up to 42.2 months ] [ Designated as safety issue: Yes ]
    Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.
  • To assess and compare the following variables in both treatment arms:
  • safety and adverse events profile
  • response rates
  • disease control rates
  • time to treatment failure
  • overall survival including 1-year survival rates
Not Provided
Not Provided
 
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC

This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival [PFS], disease control rate, best response rate, time to treatment failure [TTTF], overall survival [OS] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
  • Drug: Pemetrexed
    500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
    Other Names:
    • LY231514
    • Alimta
  • Drug: Erlotinib
    150 mg given orally (po), daily (QD), starting on the first day of the first cycle
    Other Name: Tarceva
  • Drug: Pemetrexed
    500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
    Other Names:
    • LY231514
    • Alimta
  • Drug: Erlotinib
    150 mg given po, QD, starting on the first day of the first cycle
    Other Name: Tarceva
  • Experimental: Pemetrexed (Nonsquamous)
    Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
    Intervention: Drug: Pemetrexed
  • Experimental: Pemetrexed + Erlotinib (Nonsquamous)
    Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
    Interventions:
    • Drug: Erlotinib
    • Drug: Pemetrexed
  • Experimental: Pemetrexed (Squamous)
    Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
    Intervention: Drug: Pemetrexed
  • Experimental: Pemetrexed + Erlotinib (Squamous)
    Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
    Interventions:
    • Drug: Pemetrexed
    • Drug: Erlotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
204
June 2011
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy.
  • Failure of previous treatment with one prior platinum-based chemotherapy regimen.
  • Good performance status.
  • Adequate bone marrow reserve, renal and hepatic functions.

Exclusion Criteria:

  • Serious concomitant systemic disease.
  • Inability to take oral medication.
  • Inability or unwillingness to take vitamin supplementation and corticosteroids.
  • Pregnancy / Breast-feeding.
  • Treatment with certain medicines that prevent blood from clotting.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Germany,   Hungary,   Spain,   Sweden
 
NCT00447057
10721, H3E-MC-S102
No
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP